Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Mar 27;15(1):134.
doi: 10.1186/s13256-021-02706-8.

Priming with a gonadotropin-releasing hormone agonist before immature oocyte retrieval may improve maturity of oocytes and outcome in in vitro maturation (IVM) cycle: a case report

A Smirnova  1   2 , M Anshina  1   2 , E Shalom Paz  3   4 , A Ellenbogen  5
Affiliations
Case Reports

Priming with a gonadotropin-releasing hormone agonist before immature oocyte retrieval may improve maturity of oocytes and outcome in in vitro maturation (IVM) cycle: a case report

A Smirnova et al. J Med Case Rep. .

Abstract

Background: The concept of using a gonadotropin-releasing hormone agonist (GnRH-a) instead of human chorionic gonadotropin for triggering ovulation in patients treated with an antagonist protocol for in vitro fertilization (IVF) has become a routine clinical practice. It may promote oocyte nuclear maturation, resumption of meiosis and cumulus expansion. It seems that this attempt could be beneficial in an in vitro maturation (IVM) oocyte cycle performed for polycystic ovarian syndrome as well as for other indications such as urgent fertility preservation in patients with malignancies or unusual indications.

Case presentation: We present the case of a Caucasian patient who needed fertility preservation when routine natural IVF treatment did not yield oocyte retrieval, followed by three IVM cycles, priming ovulation with a GnRH-a. In total, 12 oocytes were obtained, all matured 4.5 hours after incubation in maturation media. The fertilization rate after intracytoplasmic sperm injection was 83%. Six good-quality embryos were vitrified.

Conclusions: It seems that triggering with a GnRH-a in selected cases may replace human chorionic gonadotropin in IVM of oocytes and could be highly beneficial in terms of obtaining high-grade embryos and possible pregnancy.

Keywords: Case report; GnRH agonist priming; IVF; In vitro fertilization; In vitro maturation; Oocyte.

PubMed Disclaimer

Conflict of interest statement

None.

References

    1. Pincus G, Enzmann EV. The comparative behavior of mammalian eggs in vivo and in vitro: I. The activation of ovarian eggs. J Exp Med. 1935;62:665–675. doi: 10.1084/jem.62.5.665. - DOI - PMC - PubMed
    1. Trounson A, Wood C, Kausche A. In vitro maturation and the fertilization and developmental competence of oocytes recovered from untreated polycystic ovarian patients. Fertil Steril. 1994;62:353–362. doi: 10.1016/s0015-0282(16)56891-5. - DOI - PubMed
    1. Shalom-Paz E, Almog B, Shehata F, et al. Fertility preservation for breast-cancer patients using IVM followed by oocyte or embryo vitrification. Reprod Biomed Online. 2010;21:566–571. doi: 10.1016/j.rbmo.2010.05.003. - DOI - PubMed
    1. Shalom-Paz E, Holzer H, Son W, et al. PCOS patients can benefit from in vitro maturation (IVM) of oocytes. Eur J Obstet Gynecol Reprod Biol. 2012;165:53–56. doi: 10.1016/j.ejogrb.2012.07.001. - DOI - PubMed
    1. Smith GD. In vitro maturation of oocytes. Curr Womens Health Rep. 2001;1:143–145. - PubMed

Publication types

Substances

LinkOut - more resources